Gilead and kite announce presentation of transformative data in 1l metastatic triple-negative breast cancer, updated results in multiple myeloma and early data from novel investigational car t-cell therapy targeting brain cancer at 2025 asco and eha

Foster city, calif. & santa monica, calif.--(business wire)--gilead sciences, inc. (nasdaq: gild) will present more than 20 abstracts across both gilead and kite at the upcoming 2025 american society of clinical oncology (asco) annual meeting may 30 – june 3 and the 2025 european hematology association (eha) annual congress june 12 – 15. the studies span breast cancer and other solid tumors (glioblastoma, endometrial cancer, lung cancer, gastric cancer), as well as multiple blood cancers (multi.
CAR Ratings Summary
CAR Quant Ranking